NCT07270861 Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
| NCT ID | NCT07270861 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Peripheral T-Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2025-11-15 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2025-11-15 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms). * Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024. * Cohort B: Patients newly diagnosed from October 2025 onward. * Availability of basic diagnostic and treatment records . Exclusion Criteria: * Indeterminate diagnosis or missing pathology report. * Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center. * Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.
Contact & Investigator
Rong Tao, MD
STUDY CHAIR
Fudan University
Frequently Asked Questions
Who can join the NCT07270861 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peripheral T-Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07270861 currently recruiting?
Yes, NCT07270861 is actively recruiting participants. Contact the research team at hkutao@hotmail.com for enrollment information.
Where is the NCT07270861 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07270861 clinical trial?
NCT07270861 is sponsored by Fudan University. The principal investigator is Rong Tao, MD at Fudan University. The trial plans to enroll 3,000 participants.